| 產(chǎn)品編號(hào) | bs-13237R |
| 英文名稱 | FYCO1 Rabbit pAb |
| 中文名稱 | 鋅指蛋白FYCO1抗體 |
| 別 名 | DKFZp779K1152; FLJ13335; FYCO1; FYCO1_HUMAN; FYVE and coiled coil domain containing 1; FYVE and coiled coil domain containing protein 1; FYVE and coiled-coil domain-containing protein 1; MGC126517; MGC126519; RUFY3; RUN and FYVE domain containing 3; Zinc finger FYVE domain-containing protein 7. |
| 研究領(lǐng)域 | 腫瘤 轉(zhuǎn)錄調(diào)節(jié)因子 鋅指蛋白 表觀遺傳學(xué) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Mouse (predicted: Human,Rat,Pig,Dog) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 167 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human FYCO1: 1051-1150/1478 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
FYCO1 is a 1,478 amino acid protein that contains one RUN domain, one GOLD domain and one FYVE-type zinc finger. Expressed in heart and skeletal muscle, FYCO1 exists as multiple alternatively spliced isoforms and may play a role in transcriptional regulation events. In response to DNA damage, FYCO1 is subject to phosphorylation, probably by ATM or ATR. The gene encoding FYCO1 maps to human chromosome 3, which houses over 1,100 genes, including a chemokine receptor (CKR) gene cluster and a variety of human cancer-related gene loci. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. Function: May mediate microtubule plus end-directed vesicle transport. Subunit: Can form homodimers. Interacts (via C-terminus) with MAP1LC3B. Interacts with RAB7A; the interaction with RAB7A induces FYCO1 recruitment to late endosomal/lysosomal compartments. Subcellular Location: Cytoplasmic vesicle, autophagosome. Endosome. Lysosome. Note=Localizes to the external but not to the internal membrane of autophagosomes, and upon autophagosome/late endosome/lysosome fusion, it stays on the external surface of autolysosomes. Tissue Specificity: Expressed in heart and skeletal muscle. Post-translational modifications: Phosphorylated upon DNA damage, probably by ATM or ATR. DISEASE: Defects in FYCO1 are the cause of cataract congenital autosomal recessive type 2 (CATC2) [MIM:610019]. An opacification of the crystalline lens of the eye becoming evident at birth or in infancy. It frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Note=Pathogenic mutations in FYCO1 can affect intracellular transport of autophagocytic vesicles from the perinuclear area to the periphery, leading to an accumulation of large numbers of vesicles and hence loss of lens transparency (PubMed:21636066). Similarity: Contains 1 FYVE-type zinc finger. Contains 1 GOLD domain. Contains 1 RUN domain. SWISS: Q9BQS8 Gene ID: 79443 Database links: Entrez Gene: 79443 Human Entrez Gene: 17281 Mouse Omim: 607182 Human SwissProt: Q9BQS8 Human SwissProt: Q8VDC1 Mouse Unigene: 729060 Human Unigene: 252941 Mouse |
| 產(chǎn)品圖片 |
Tissue/cell: mouse heart tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-FYCO1 Polyclonal Antibody, Unconjugated(bs-13237R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
